Developing an intervention for cancer patients prescribed oral chemotherapy: A generic patient diary

European Journal of Cancer Care

Volumn 19, Issue SUPPL. 1, 2010, Pages 21-28

  Oakley, C ^a   Johnson, J ^b   Ream, E ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Oral chemotherapy; Patient held diary; Self efficacy; Self management

Indexed keywords

EID: 77954847729     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2010.01198.x     Document Type: Article

References (42)

1. Bloomfield J, Plant H. Oral anti-cancer therapies. European Journal of Cancer Care 2006, 15:404-418.
2. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). European Journal of Oncology Nursing 2004, 8:S41-S53.
3. Cresswell J. Research Design: Qualitative, Quantitative and Mixed Methods Approaches 2003, 2nd, edn., Sage Publications, Inc, London, UK
4. Dauz Williams P, Piamjariyakul U, Ducey K, Badura J, Boltz KD, Olberding K, Wingate A, Williams A. Cancer treatment, symptom monitoring, and self care in adults. Cancer Nursing 2006, 29:347-355.
5. Deery P, Faithfull S. Developing a patient pathway to deliver a new oral chemotherapy. Professional Nurse 2003, 19:102-106.
6. Dixon-Woods M. What can ethnography do for quality and safety in healthcare? Quality and Safety in Healthcare 2003, 12:326-327.
7. Fenlon D, Foster C. Self Management Support: A Review of the Evidence 2009, Macmillan Research Unit, University of Southampton, Southampton, UK
8. Gerbrecht B, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. European Journal of Oncology Nursing 2004, 8:S63-S71.
9. Green J, Thorogood N. Qualitative Methods for Health Research 2004, Sage Publications, London, UK
10. Hammersley M, Atkinson P. Ethnography: Principles in Practice 1995, Tavistoke, London, UK
11. Hartigan K. Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing 2002, 7:21-24. supplement
12. Kav S, Bostanci H. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment in Turkey. Supportive Cancer Care 2006, 14:1252-1257.
13. Lebovits AH, Strainn JJ, Schleifer SJ. Patient non-compliance with self-administered chemotherapy. Cancer 1990, 65:17-22.
14. Lee CR, Nicholson PW, Souhami RL, Slevin ML, Hall MR, Deshmukh AA. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. British Journal of Cancer 1993, 67:630-634.
15. Lee CR, Nicholson PW, Lederman JA, Rustin GJS. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Europeon Journal of Gynaecological Oncology 1996, 17:99-103.
16. Lev E, Paul D, Owen S. Age, self efficacy, and change in patients' adjustment to cancer. Cancer Practice 1999, 7:170-176.
17. Levanthal H, Nerenz d, Leventhal E, Love R, Bendena L. The behavioural dynamics of clinical trials. Preventative Medicine 1991, 20:132-146.
18. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, Kishbaugh C, Shelton DR, Anderson Johnson C. Compliance with oral drug therapy in patients with hematologic malignancy. Journal of Clinical Oncology 1987, 5:1469-1476.
19. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus IV palliative chemotherapy. Journal of Clinical Oncology 1997, 15:110-115.
20. Lorig K, Sobel D, Stewart A, Brown B, Bandura A, Ritter P, Gonzalez V, Laurent D, Holman H. Evidence suggested that a chronic disease self management program can improve health status while reducing hospitalization. Medical Care 1999, 37:5-14.
21. McCaughan EM, Thompson KA. Information needs of cancer patients receiving chemotherapy at a day-case unit in Northern Ireland. Journal of Clinical Nursing 2000, 9:851-858.
22. McKendrick JJ, Cassidy J, Chakrapee-Sirisuk S, Fountzilas G, Iveson T, Jelic S, Karnicka-Mlodkowska H, Ostojic R, Scheithauer W, Twelves C. Capecitabine (X) is resource saving compared with IV. bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: Medical resource utilization (MRU) data from a large phase III trial (X-ACT). Journal of Clinical Oncology 2004, 22(14):3578. ASCO Annual Meeting Proceedings (Post-Meeting Edition, Suppl., July 15 Supplement), 2004
23. Macleod A, Branch A, Cassidy J, McDonald A, Mohammed N. A nurse-pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiences. European Journal of Oncology Nursing 2007, 11:247-254.
24. Merluzzi TV, Sanchez MA. Assessment of self efficacy and coping with cancer: development and validation of the cancer behaviour inventory. Health Psychology 1997, 16:163-170.
25. Molassiotis A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, Swindell R, Todd C, Luker K. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. Journal of Clinical Oncology 2009, 27:6191-6198.
26. Developing and Evaluating Complex Interventions: New Guidance. 2008, http://www.mrc.ac.uk/complexinterventionsguidance/, Medical Research Council (MRC), Available at:
27. Chemotherapy Services in England: Ensuring Quality and Safety 2009, National Chemotherapy Advisory Group, DH, London, UK
28. Risks of Incorrect Dosing of Oral Anti-Cancer Medicines (NPSA/2008/RRR001) 2008, National Patient Safety Agency, DH, London, UK
29. Technology Appraisal, No. 61. 2003, NICE, Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003
30. Partridge AH, Avon J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 2002, 94:652-661.
31. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology 2003, 21:602-606.
32. Partridge AH, LaFountain A, Mayer E, Taylor SB, Winer E, Asnis-Alibozek AA. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. Journal of Clinical Oncology 2008, 26940:556-562.
33. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. European Journal of Cancer 1994, 30A:1326-1336.
34. Redfern J, Rudd AD, Wolfe CD, McKevitt C. Stop Stroke; Development of an innovative intervention to improve risk factor management after stroke. Patient Education and Counselling 2008, 72:201-209.
35. Ritchie J, Lewis J. Qualitative Research Practice: A Guide for Social Science Students and Researchers 2006, 5th, edn., SAGE Publications Ltd, London, UK
36. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. Analysing Qualitative Data 2004, 173-194. Bryman A, Burgess R. In, ed., pp., Routledge, West Sussex, UK
37. Savage J. Ethnography and health care. British Medical Journal 2000, 321:1400-1402.
38. Skalla KA, Bakitas M, Furstenberg C, Ahles T, Henderson JV. Patients need for information about cancer therapy. Oncology Nursing Forum 2004, 31:313-319.
39. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K. Capectiabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Journal of Cancer 2001, 37:597-604. on behalf of the Xeloda colorectal cancer study group
40. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology 2006, 17:239-245.
41. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology 1993, 11:1189-1197.
42. Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. British Medical Journal 2007, BMJ, doi:10.1136/BMJ.39069.489757.55; published 12 January 2007